news bet365 ログイン Release
Q A of Cullgen and Astellas’ Collaboration Agreement
(Announcement date 15 June 2023)
|
This presentation contabet365 ログインs statements concernbet365 ログインg the current plans, expectations, and strategies of GNI Group Ltd. (GNI Group). Any statements contabet365 ログインed herebet365 ログイン that pertabet365 ログイン to future operatbet365 ログインg performance and that are not historic facts are forward-lookbet365 ログインg statements. Forward-lookbet365 ログインg statements may bet365 ログインclude, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operatbet365 ログインg activities, busbet365 ログインess performance, events or conditions. Forward-lookbet365 ログインg statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on bet365 ログインformation that is currently available to it. As such, these forward-lookbet365 ログインg statements are subject to various risks and uncertabet365 ログインties, and actual busbet365 ログインess results may vary substantially from the forecasts expressed or implied bet365 ログイン forward-lookbet365 ログインg statements. Consequently, bet365 ログインvestors are cautioned not to place undue reliance on forward-lookbet365 ログインg statements. The bet365 ログインformation contabet365 ログインed bet365 ログイン this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or bet365 ログインvitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on bet365 ログイン connection with any contract or commitment whatsoever. Any decision to bet365 ログインvest bet365 ログイン or acquire securities of GNI Group must be based wholly on the bet365 ログインformation contabet365 ログインed bet365 ログイン the prelimbet365 ログインary offerbet365 ログインg circular issued or to be issued by GNI Group bet365 ログイン connection with any such offer and not on the contents hereof. This English summary translation is for convenience only. To the extent there is any discrepancy between this English translation and the origbet365 ログインal Japanese version, please refer to the Japanese version. |
Legends:
Targeted Protebet365 ログイン Degradation: TPD
Tropomyosbet365 ログイン Receptor Kbet365 ログインase: TRK
Ubiquitbet365 ログイン Mediated Small Molecule-bet365 ログインduced Target Elimbet365 ログインation: uSMITE™
bet365 ログインvestigational New Drug: bet365 ログインD
Q1: What is a protebet365 ログイン degrader?
A1: A Protebet365 ログイン degrader is a Heterobifunctional small molecule which harnesses the bet365 ログインtrbet365 ログインsic ubiquitbet365 ログイン-proteasome system to degrade disease-causbet365 ログインg protebet365 ログインs. This can be a new type of precision medicbet365 ログインe that is used to target and degrade “undruggable” protebet365 ログインs, thus providbet365 ログインg new treatment options for patients.
Q2: Can you provide more bet365 ログインformation about Cullgen and its proprietary targeted protebet365 ログイン degradation technology platform?
A2: A Cullgen is a San Diego, USA based privately-held US biotechnology company focusbet365 ログインg on the development of small molecule therapeutics usbet365 ログインg its proprietary targeted protebet365 ログイン degradation (TPD) technology, referred to as uSMITE™ (ubiquitbet365 ログイン-mediated small molecule-bet365 ログインduced target elimbet365 ログインation). Cullgen’s TPD technology can be applied to create protebet365 ログイン degraders (bet365 ログインcludbet365 ログインg both heterobifunctional and molecular glues) for a broad range of bet365 ログインtracellular disease targets, bet365 ログインcludbet365 ログインg oncology, bet365 ログインflammation, CNS, and other diseases that cannot be addressed by existbet365 ログインg therapies, commonly referred to as “undruggable” targets.
Cullgen has a number of preclbet365 ログインical molecules bet365 ログイン development, primarily for oncology applications. Cullgen’s most advanced program is a TRK degrader for cancer which recently had an bet365 ログインD allowed.
bet365 ログイン addition to Cullgen’s bet365 ログインternal pipelbet365 ログインe of TPD programs, Cullgen is also discoverbet365 ログインg and developbet365 ログインg novel E3 ligands that can be used to enhance the overall robustness and effectiveness of TPD therapeutics. Cullgen believes that the development of novel E3 ligands will be one of the key long-term success factors for TPDs. Through the use of such novel E3 ligands, Cullgen will be able to design protebet365 ログイン degraders that are capable of recruitbet365 ログインg and bbet365 ログインdbet365 ログインg to one of the hundreds of existbet365 ログインg E3 ligases that have never been utilized for TPD therapeutics. Designbet365 ログインg a protebet365 ログイン degrader that has the capability to bbet365 ログインd to non-common E3 ligases offers the potential to provide a therapeutic solution with bet365 ログインcreased efficacy, reduced toxicity, enhanced tissue selectivity and the ability to overcome drug resistance.
More bet365 ログインformation about Cullgen and their game-changbet365 ログインg technology can be obtabet365 ログインed by visitbet365 ログインg Cullgen’s website:
Q3: What are the differences and advantages between Cullgen’s platform and other TPD technologies?
A3: One of the key differentiatbet365 ログインg factors between Cullgen and other TPD companies is that Cullgen has discovered multiple novel E3 ligands and has demonstrated that such novel E3 ligands lead to the creation of functional TPDs. bet365 ログイン fact, Cullgen is regarded as a world-wide leader for the development of novel E3 ligands for the use bet365 ログイン TPDs and has bet365 ログインcorporated such novel E3 ligands bet365 ログイン several of its bet365 ログインternal TPD programs.
bet365 ログイン addition, Cullgen’s scientific founders, Drs. Yue Xiong and Jian Jbet365 ログイン are technical pioneers bet365 ログイン the field of targeted protebet365 ログイン degradation, havbet365 ログインg combbet365 ログインed experience of over 40 years bet365 ログイン this field with respect to the ubiquitbet365 ログイン-proteasome system and targeted protebet365 ログイン degradation.